Global Hemoperfusion Market Size By Type (Activated Carbon Adsorption, Resin Adsorption), By Application (Hepatic Encephalopathy, Certain Autoimmune Diseases), By Region, And Segment Forecasts, 2023 t...

The Global Hemoperfusion Market was valued at USD 610 million in 2023 and is projected to reach USD 1.16 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the forecast period from 2023 to 2031. The market is witnessing strong growth due to increasing incidences of chronic kidney diseases, drug overdoses, and severe inflammatory conditions. Hemoperfusion, a method for removing toxins from the blood using adsorbent substances, is gaining traction as a complementary therapy to dialysis, especially in acute settings such as sepsis and liver failure.

Drivers:

1. Rising Prevalence of Chronic Diseases:

An increase in patients suffering from chronic kidney disease, liver failure, and autoimmune disorders is propelling demand for hemoperfusion treatments, especially in critical care environments.

2. Technological Advancements in Adsorbent Cartridges:

Modern hemoperfusion cartridges have improved toxin removal capabilities, biocompatibility, and patient safety, making them more attractive for healthcare providers.

3. Growing Awareness and Adoption in Emerging Markets:

Enhanced awareness campaigns by global health organizations and increased healthcare infrastructure investment in Asia-Pacific and Latin America are contributing to market expansion.

Restraints:

1. High Cost of Equipment and Consumables:

Hemoperfusion therapy requires specific equipment and frequent cartridge replacements, making it an expensive option for underfunded healthcare settings.

2. Limited Reimbursement Policies:

In many countries, hemoperfusion is not widely reimbursed by health insurance systems, which limits its adoption in routine clinical practices.

Opportunity:

1. Expansion into Critical Care Applications:

With a rising focus on intensive care units (ICUs) and extracorporeal blood purification, hemoperfusion is gaining new ground in treating sepsis, COVID-19-related complications, and cytokine storms.

2. Integration with Dialysis and CRRT Platforms:

Manufacturers are innovating by integrating hemoperfusion with continuous renal replacement therapy (CRRT) systems, increasing treatment versatility and adoption in ICUs.

Market by System Type Insights:

Based on system type, the Resin Adsorbent Cartridges segment dominated the market in 2023. These cartridges are widely used due to their high adsorption efficiency and cost-effectiveness. Meanwhile, the Activated Carbon Cartridges segment is expected to witness robust growth, particularly in detoxification and drug overdose treatments, where rapid toxin removal is critical.

Market by End-use Insights:

In terms of end-use, Hospitals and Intensive Care Units (ICUs) held the largest market share in 2023, owing to the increased adoption of hemoperfusion in emergency and acute care settings. The Dialysis Centers segment is also growing steadily, driven by the increasing number of chronic kidney disease (CKD) patients requiring toxin clearance beyond traditional dialysis.

Market by Regional Insights:

North America led the global hemoperfusion market in 2023, driven by its advanced healthcare infrastructure, high prevalence of kidney diseases, and strong presence of key market players. However, the Asia-Pacific region is expected to witness the fastest growth rate through 2031 due to increasing healthcare investments, rising awareness, and a rapidly expanding patient population in countries such as China, India, and South Korea.

Competitive Scenario:

Prominent players in the global hemoperfusion market include Jafron Biomedical Co., Ltd., Baxter International Inc., CytoSorbents Corporation, Asahi Kasei Medical Co., Ltd., Nikkiso Co., Ltd., Kaneka Corporation, and Toray Medical Co., Ltd. These companies are investing in R&D, forming strategic partnerships with hospitals and research institutions, and expanding into emerging markets.

Key Market Developments:

In 2023, CytoSorbents launched a next-generation hemoperfusion cartridge designed to target cytokine removal in critical care.

In 2024, Jafron Biomedical received expanded regulatory approvals for its HA Series cartridges in Latin America and Southeast Asia.

Baxter International initiated a clinical trial in 2025 evaluating hemoperfusion combined with CRRT for septic shock management in ICU settings.

Scope of Work – Global Hemoperfusion Market

Report Metric Details

Market Size (2023) USD 610 million

Projected Market Size (2031) USD 1.16 billion

CAGR (2023–2031) 8.3%

Market Segments By System Type (Resin Cartridges, Activated Carbon Cartridges),

By End-use (Hospitals, Dialysis Centers, Others)

Growth Drivers Rising chronic illness prevalence, adoption in critical care, and cartridge technology advancements

Opportunities Integration with CRRT, expansion in emerging economies, sepsis treatment applications

FAQs:

1. What is the current market size of the Global Hemoperfusion Market?

The market was valued at USD 610 million in 2023.

2. What is the major growth driver of the Global Hemoperfusion Market?

The increasing prevalence of chronic diseases and the adoption of hemoperfusion in critical care settings are key drivers.

3. Which is the largest region during the forecast period in the Global Hemoperfusion Market?

North America held the largest market share in 2023, but Asia-Pacific is expected to grow the fastest through 2031.

4. Which segment accounted for the largest market share in Global Hemoperfusion Market?

The Hospitals and Intensive Care Units (ICUs) segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Hemoperfusion Market?

Key players include Jafron Biomedical, CytoSorbents, Baxter International, Asahi Kasei, Nikkiso, Kaneka, and Toray Medical.